Department of Radiology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Department of Radiological Science, College of Health Science, Kangwon National University, Samcheok-si, Korea.
Diagn Interv Radiol. 2021 Jul;27(4):519-523. doi: 10.5152/dir.2021.20253.
The study aimed to evaluate the safety and clinical efficacy of transcatheter arterial embolization (TAE) for the treatment of arterial esophageal bleeding.
Nine patients (8 male, 1 female; mean age, 62.3±7.5 years) who underwent TAE for arterial esophageal bleeding between January 2004 and January 2020 were included. Preceding endoscopic treatment was unsuccessful in five patients and was not attempted in four patients due to the non-cooperation of the patients in endoscopic treatment. The etiologies of bleeding were esophageal cancer (n=4), Mallory-Weiss syndrome (n=3), erosive esophagitis (n=1), and esophageal ulcer (n=1). Technical and clinical success, recurrent bleeding, procedure-related complications, and clinical outcomes were retrospectively reviewed.
The angiographic findings for bleeding were contrast media extravasation (n=8) or tumor staining without a definite bleeding focus (n=1). The bleeding focus at the distal esophagus (n=8) was the left gastric artery, whereas that at the middle esophagus (n=1) was the right bronchial artery. Technical success was achieved in all patients. The embolic agents were n-butyl cyanoacrylate (NBCA, n=5), gelatin sponge particles (n=2), microcoils (n=1), and NBCA with gelatin sponge particles (n=1). Clinical success was achieved in 77.8% of cases (7/9); two patients with recurrent bleeding one day after the first TAE showed culprit arteries different from the bleeding foci at the first TAE. One patient who underwent embolization of both the left and short gastric arteries died of gastric infract/perforation one month after TAE.
TAE can be an alternative to the treatment of arterial esophageal bleeding. TAE can be attempted in the treatment of recurrent bleeding, but there is a risk of ischemia/infarct in the gastrointestinal tract involved.
本研究旨在评估经导管动脉栓塞术(TAE)治疗动脉性食管出血的安全性和临床疗效。
纳入 2004 年 1 月至 2020 年 1 月期间因动脉性食管出血而行 TAE 治疗的 9 例患者(8 例男性,1 例女性;平均年龄 62.3±7.5 岁)。5 例患者先前的内镜治疗无效,4 例患者由于不配合内镜治疗而未尝试内镜治疗。出血的病因包括食管癌(n=4)、Mallory-Weiss 综合征(n=3)、侵蚀性食管炎(n=1)和食管溃疡(n=1)。回顾性分析了技术和临床成功率、再出血、与操作相关的并发症和临床结局。
出血的血管造影表现为造影剂外渗(n=8)或无明确出血灶的肿瘤染色(n=1)。远端食管的出血灶(n=8)为胃左动脉,而中段食管的出血灶(n=1)为右支气管动脉。所有患者均达到技术成功。栓塞剂为 n-丁基氰基丙烯酸酯(NBCA,n=5)、明胶海绵颗粒(n=2)、微线圈(n=1)和 NBCA 与明胶海绵颗粒(n=1)。77.8%(7/9)的患者达到临床成功;2 例首次 TAE 后 1 天再次出血的患者显示出血动脉与首次 TAE 的出血灶不同。1 例接受左胃动脉和短胃动脉栓塞的患者在 TAE 后 1 个月死于胃梗死/穿孔。
TAE 是治疗动脉性食管出血的一种替代方法。TAE 可用于治疗再出血,但存在胃肠道缺血/梗死的风险。